Latest Ratios: P/E Ratio -1.3x · EV/EBITDA N/A · ROE -103.9%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $16M | $61M | — | — | — | — | — | — | $254M |
| Enterprise Value | $54M | $16M | $67M | — | — | — | — | — | — | $254M |
| P/E Ratio → | -1.32 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1695.27 | 497.91 | 25.97 | — | — | — | — | — | — | — |
| P/B Ratio | 1.02 | 1.02 | 8.37 | — | — | — | — | — | — | 859.87 |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 497.81 | 28.92 | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | 75.32 | — | — | — | — | — | — | 1127.54 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1225.0% | -1225.0% | 100.0% | — | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | -13343.8% | -13343.8% | 23.7% | — | -6808.0% | -6808.0% | — | — | — | — |
| Net Profit Margin | -36993.8% | -36993.8% | -88.0% | — | -14102.0% | -14102.0% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -103.9% | -103.9% | -28.3% | -14.2% | -19.4% | -35.3% | -1696.4% | -404.2% | -39.9% | -138.3% |
| ROA | -62.8% | -62.8% | -10.1% | -9.5% | -13.7% | -25.0% | -802.8% | -353.5% | -36.5% | -127.3% |
| ROIC | -21.6% | -21.6% | — | -7.3% | -5.4% | -9.7% | -33156.1% | — | -21.6% | — |
| ROCE | -31.9% | -31.9% | 5.3% | -12.0% | -8.5% | -15.5% | -1525.3% | -465.8% | -13.8% | 21.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 1.23 | 0.43 | 0.31 | 0.31 | — | — | — | — |
| Debt / EBITDA | — | — | 9.92 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | 0.95 | 0.43 | 0.31 | 0.31 | — | -1.03 | -1.04 | -0.18 |
| Net Debt / EBITDA | — | — | 7.68 | — | — | — | — | — | -1.49 | -0.23 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -17.22 | -17.22 | -11.14 | -9.07 | -7.37 | -7.37 | — | — | — | — |
Net cash position: cash ($3000) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.35 | 0.35 | 0.25 | 0.03 | 0.01 | 0.02 | 3.98 | 5.31 | 10.81 | 12.61 |
| Quick Ratio | 0.30 | 0.30 | 0.25 | 0.03 | 0.01 | 0.02 | 3.98 | 5.31 | 10.81 | 12.61 |
| Cash Ratio | 0.00 | 0.00 | 0.20 | 0.00 | 0.00 | 0.00 | 2.89 | 4.50 | 10.20 | 2.04 |
| Asset Turnover | — | 0.00 | 0.11 | — | 0.00 | 0.00 | — | — | — | — |
| Inventory Turnover | 6.73 | 6.73 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 2315.47 | 28.81 | — | 116.80 | 1438.10 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — | — | 0.0% |
| Shares Outstanding | — | $32M | $42M | $191M | $11M | $60M | $70496 | $12M | $10M | $10M |
Imminent insolvency and liquidity
Based on reported figures, IBO trades at a P/S ratio of 1586.47, a multiple that appears disconnected from fundamental reality given the company's near-zero revenue and the absence of a viable path toward commercial scale in its specialized biotechnology and functional food technology segments.
The extreme P/S multiple suggests that the market is pricing the company as a speculative option on intellectual property rather than a functioning business. Investors should monitor whether this valuation is supported by any tangible progress in patent monetization, as the current lack of earnings renders traditional P/E or EV/EBITDA metrics entirely inapplicable.
As reported in financial statements, IBO's ROIC has consistently trended in negative territory, reaching -11.4% in 2026Q1, which indicates that the company is failing to generate any economic return on its invested capital while simultaneously eroding its remaining asset base through persistent operating losses.
The negative ROIC trend highlights a fundamental inability to deploy capital effectively across the firm's disparate business segments. This decay suggests that the company's R&D and administrative expenditures are not creating value, but rather consuming the firm's limited resources without producing a corresponding increase in commercial output.
According to recent SEC filings, the company's cash conversion cycle has reached extreme levels, such as the 2490-day cycle reported in 2026Q1, which underscores a complete lack of operational velocity and an inability to convert its intellectual property assets into meaningful, recurring cash inflows.
The erratic nature of the DSO and DIO metrics suggests that the company lacks a standardized sales or production process. This inefficiency appears to be a structural byproduct of a business model that relies on sporadic, non-recurring licensing events rather than a repeatable commercial cycle.
Based on the provided balance sheet data, the current ratio has deteriorated to 0.22 as of 2026Q1, indicating that the company lacks the liquid assets necessary to meet its short-term obligations without immediate, likely dilutive, external capital injections to sustain its ongoing operations.
The company's liquidity position is severely compromised, with cash reserves effectively depleted to nominal levels. This vulnerability suggests that the firm is in a state of existential risk, where any delay in securing funding could lead to an inability to maintain its patent portfolio or meet basic corporate reporting requirements.
The P/B ratio of 0.96 is the most commonly misapplied metric for this business model, as it falsely implies that the company's book value represents tangible assets that could be liquidated to satisfy creditors in the event of a total business failure.
Because the company's asset base is heavily weighted toward intangible goodwill and speculative intellectual property, the P/B ratio fails to account for the lack of marketability of these assets. Analysts should instead focus on the cash-to-burn ratio, which provides a more accurate, albeit grim, assessment of the company's remaining runway.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IBO stock.
Impact BioMedical Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
Impact BioMedical Inc.'s return on equity (ROE) is -103.9%. The historical average is -97.9%.
Based on historical data, Impact BioMedical Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Impact BioMedical Inc. has -1225.0% gross margin and -13343.8% operating margin.